Motus GI's Pure-Vu EVS Gastro Used in First Procedure
Provided by
Dow Jones
By Chris Wack
Motus GI Holdings said its Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.
The medical technology company said the case was completed by a gastroenterologist and associate professor of medicine at the University of Minnesota.
The Pure-Vu EVS Gastro, which received clearance from the Food and Drug Administration in late October, is intended for patients who suffer from upper gastrointestinal bleeding. The Pure-Vu EVS Gastro targets blood, blood clots and other debris in the upper GI tract.
Motus GI shares were up 43% at $5.11 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 10, 2023 08:37 ET (13:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States